X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (65) 65
index medicus (63) 63
female (55) 55
male (54) 54
oncology (53) 53
middle aged (47) 47
aged (42) 42
melanoma (41) 41
adult (38) 38
melanoma - drug therapy (35) 35
cancer (34) 34
ipilimumab (31) 31
treatment outcome (29) 29
immunotherapy (25) 25
metastasis (25) 25
aged, 80 and over (24) 24
skin neoplasms - drug therapy (22) 22
survival (21) 21
antineoplastic agents - therapeutic use (20) 20
clinical trials (20) 20
patients (19) 19
care and treatment (18) 18
melanoma - pathology (18) 18
metastatic melanoma (18) 18
antibodies, monoclonal - adverse effects (17) 17
antibodies, monoclonal - therapeutic use (17) 17
chemotherapy (17) 17
skin neoplasms - pathology (17) 17
tumors (17) 17
antibodies, monoclonal - administration & dosage (15) 15
hematology, oncology and palliative medicine (15) 15
neoplasm staging (15) 15
studies (15) 15
antineoplastic agents - adverse effects (14) 14
expression (13) 13
research (13) 13
analysis (12) 12
immunology (12) 12
nivolumab (12) 12
abridged index medicus (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
disease-free survival (11) 11
medicine & public health (11) 11
medicine, general & internal (11) 11
pembrolizumab (11) 11
solid tumors (11) 11
therapy (11) 11
young adult (11) 11
antineoplastic agents - administration & dosage (10) 10
apoptosis (10) 10
article (10) 10
blockade (10) 10
drug therapy (10) 10
kaplan-meier estimate (10) 10
medical research (10) 10
melanoma - genetics (10) 10
metastases (10) 10
mutation (10) 10
safety (10) 10
adolescent (9) 9
drug administration schedule (9) 9
melanoma - immunology (9) 9
melanoma - secondary (9) 9
antineoplastic agents (8) 8
carcinoma (8) 8
complications and side effects (8) 8
medical prognosis (8) 8
multicenter (8) 8
prognosis (8) 8
surgery (8) 8
survival analysis (8) 8
antimitotic agents (7) 7
double-blind method (7) 7
follow-up studies (7) 7
lung neoplasms - drug therapy (7) 7
melanoma - therapy (7) 7
monoclonal antibodies (7) 7
proto-oncogene proteins b-raf - genetics (7) 7
toxicity (7) 7
animals (6) 6
antibodies, monoclonal, humanized - therapeutic use (6) 6
antitumor activity (6) 6
body weight (6) 6
cancer research (6) 6
cancer therapies (6) 6
cytotoxicity (6) 6
disease progression (6) 6
dosage and administration (6) 6
dose-response relationship, drug (6) 6
drug dosages (6) 6
drug resistance, neoplasm (6) 6
immune checkpoint (6) 6
indoles - therapeutic use (6) 6
ligands (6) 6
medicine, experimental (6) 6
melanoma - mortality (6) 6
pd-1 protein (6) 6
skin cancer (6) 6
skin neoplasms - genetics (6) 6
skin neoplasms - immunology (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Petrylak, Daniel and Petrylak, Daniel P and de Wit, Ronald and Chi, Kim Nguyen and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Yu-Li and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor and Percent, Ivor J and Lee, Yun-Gyoo and Lee, Hyo Jin and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia Z and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Sarid, David and Scagliotti, Giorgio Vittorio and Bracarda, Sergio and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and Hashine, Katsuyoshi and ... and RANGE Study Investigators and RANGE study investigators
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed... 
BREAST-CANCER | BLADDER-CANCER | LUNG-CANCER | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | FOLLOW-UP | OPEN-LABEL | FACTOR RECEPTOR-2 | II TRIAL | ENDOTHELIAL GROWTH-FACTOR | MEDICINE, GENERAL & INTERNAL | CISPLATIN | DOXORUBICIN | METHOTREXATE | VINBLASTINE | COMBINATION | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. CT058 - CT058
Journal Article
Journal Article
Journal Article
Journal of Applied Biomedicine, ISSN 1214-021X, 01/2017, Volume 15, Issue 1, pp. 71 - 80
Proposed molecular mechanisms responsible for selective cytotoxic activity of stem bark extract towards human colorectal carcinoma cells. The current study... 
Signalling pathways | Programmed cell death | Terpenes | Mesua ferrea | ROS | ANGIOGENESIS | PHOSPHORYLATION | NATURAL-PRODUCTS | TARGETING APOPTOSIS | DRUG DISCOVERY | MULTIPLE SIGNALING PATHWAYS | COLON-CANCER | PHARMACOLOGY & PHARMACY | PROTEINS | EXPRESSION | MODULATION
Journal Article